Archives
-
Thrombin Biology, Evidence, and Research Context
2026-10-05
A source-grounded overview of thrombin as a coagulation cascade enzyme, the evidentiary limits of a short thrombin B-chain fragment, and why a SARS-CoV-2 protease study should not be interpreted as evidence for thrombin activity or therapeutic use.
-
LY2109761 and TGF-β Signaling: Evidence Overview
2026-10-04
LY2109761 is described by APExBIO as a TGF-β receptor type I and II dual inhibitor for research on Smad signaling, cancer biology, fibrosis, and cellular plasticity. This overview separates supplier-reported properties from findings in the supplied glioblastoma study, which evaluated resveratrol rather than LY2109761, and explains what the available evidence can—and cannot—support.
-
Sulfisomidine: hPON1 and Microbial Workflows
2026-10-01
Sulfisomidine, also known as sulfamethin, connects bacterial folate-pathway experiments with mechanistic human serum paraoxonase 1 studies. This workflow-focused guide explains stock preparation, mixed-type inhibition analysis, microbial testing, troubleshooting, and responsible cross-domain interpretation.
-
AEBSF.HCl: From Protease Control to Translation
2026-10-01
AEBSF.HCl, or 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride, is more than a routine serine protease inhibitor. Used with appropriate orthogonal controls, it can help translational researchers separate serine-protease-dependent biology from the lysosomal cathepsin axis that drives MLKL-associated necroptosis, while also supporting amyloid precursor protein and cell-lysis studies.
-
Amplex Red Workflows for H2O2 and HRP Assays
2026-09-30
Amplex Red turns hydrogen peroxide formation into a quantitative resorufin signal for oxidase, HRP, cellular ROS, and enzyme-immobilization studies. This practical guide combines plate-based assay design with the reference study’s nanoelectrode workflow, emphasizing calibration, controls, and troubleshooting.
-
Antimycin A4: Dual-Pathway Research Workflows
2026-09-30
Antimycin A4 enables parallel investigation of ATP-citrate lyase activity, lipid precursor supply, and mitochondrial electron transport. This practical guide separates those effects with enzyme-first controls, cell-based validation, storage guidance, and troubleshooting logic.
-
Grazoprevir Hydrate: From Target to Assay
2026-09-29
Grazoprevir hydrate is an HCV NS3/4A protease inhibitor with genotype-sensitive antiviral potency and strong translational value. This article connects mechanism, pharmacokinetics, clinical context, and assay design to support more rigorous hepatitis C research decisions.
-
Merbromin as a Mixed-Type SARS-CoV-2 3CLpro Inhibitor
2026-09-29
The reference study screened approximately 6,000 compounds and identified merbromin as a selective inhibitor of the SARS-CoV-2 main protease, 3CLpro/Mpro. Enzyme kinetics, binding assays, and molecular docking supported a mixed-type mechanism involving more than one binding site, providing a useful framework for validating antiviral protease inhibitors.
-
Vancomycin Hydrochloride: Mechanism to Translation
2026-09-28
A mechanism-first guide to using Vancomycin hydrochloride as a Gram-positive benchmark, resistance probe, and translational research tool.
-
BMS 309403: Testing FABP4 Causality in Foam Cells
2026-09-28
BMS 309403 is a potent FABP4 inhibitor for probing how fatty-acid handling contributes to macrophage foam-cell formation. This article focuses on what the 2025 SERCA2 study adds to experimental design: a way to distinguish upstream calcium-signaling defects from downstream FABP4-dependent lipid phenotypes.
-
Z-LEHD-FMK: Caspase-9 Inhibition in Research
2026-09-27
Z-LEHD-FMK is an irreversible caspase-9 inhibitor used to probe caspase-9-dependent apoptosis. This article distinguishes the compound’s vendor-described uses from the chicken GSDME study, which examines RNA-virus-induced pyroptosis and does not test Z-LEHD-FMK.
-
From ALOX5 Biology to Sensitive CRSwNP Protein Evidence
2026-09-26
Huang et al. connect ALOX5 with ferroptosis-associated epithelial barrier dysfunction in CRSwNP. This article considers what their validation means for translational Western blot strategy—and where ultrasensitive chemiluminescent detection can help without overstating the evidence.
-
Bromodomain Inhibitor, (+)-JQ1 Workflows
2026-09-25
Turn BET biology into practical experiments with a workflow for dosing, apoptosis readouts, and combination studies in breast cancer models. Learn how to interpret the BRD4–RAC1 findings without mistaking biochemical binding or preclinical results for clinical efficacy.
-
Salmonella Haem Rewires Phagocytosis and Infection
2026-09-25
The study identifies SirM as a Salmonella methyltransferase that increases HemL activity and haem production, helping the pathogen inhibit macrophage phagocytosis and promote infection in mice. Its findings link bacterial haem metabolism to host-cell responses, extending the significance of haem biosynthesis beyond its established role in iron acquisition.
-
Poly (I:C) Workflows for Macrophage Inflammation
2026-09-24
Use Poly (I:C) to build a controlled, TLR3-centered inflammatory model and test how macrophage state changes downstream signaling. This workflow connects dose-and-time optimization to a recent CXCL10–CXCR3–LAMP1 study, while keeping practical assay recommendations distinct from the paper’s reported findings.